BRIEF published on 03/04/2026 at 22:35, 11 days 10 hours ago DBV Technologies will participate in investor conferences in March Investor Conferences Biopharmaceutical DBV Technologies March 2026 Citizens Life Sciences
BRIEF published on 03/04/2026 at 22:35, 11 days 10 hours ago DBV Technologies Announces Participation in March Investor Conferences Investor Conferences Biopharmaceutical DBV Technologies Food Allergies VIASKIN Patch
PRESS RELEASE published on 03/04/2026 at 22:30, 11 days 10 hours ago DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies to participate in upcoming investor conferences to present its late-stage biopharmaceutical developments for food allergies. Company uses proprietary VIASKIN patch technology for treatment Investor Conferences Biopharmaceutical DBV Technologies Food Allergies VIASKIN Patch
BRIEF published on 03/03/2026 at 22:35, 12 days 10 hours ago DBV Technologies: Update on voting rights and shares Euronext Paris Share Capital Voting Rights Financial Regulations DBV Technologies
BRIEF published on 03/03/2026 at 22:35, 12 days 10 hours ago DBV Technologies: February 2026 Voting Rights and Shares Update Voting Rights Shares DBV Technologies NYSE Euronext Paris February 2026
PRESS RELEASE published on 03/03/2026 at 22:30, 12 days 10 hours ago Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 Important update on total voting rights and shares as of February 28, 2026 for NYSE Euronext Paris. Total gross voting rights: 278,352,082 Shares Total Voting Rights Regulations NYSE Euronext Paris February 28 2026
BRIEF published on 03/02/2026 at 15:53, 13 days 17 hours ago JP Morgan's investment in DBV Technologies reaches new thresholds Crossing Thresholds Equity Swaps Shares And Voting Rights DBV Technologies JP Morgan
BRIEF published on 02/28/2026 at 20:30, 15 days 12 hours ago DBV Technologies reveals promising new results for VIASKIN Peanut Clinical Study Immunotherapy DBV Technologies Food Allergies Viaskin Peanut
BRIEF published on 02/28/2026 at 20:30, 15 days 12 hours ago DBV Technologies Unveils Promising Phase 3 VITESSE Study Results at AAAAI 2026 DBV Technologies Phase 3 Results Viaskin Peanut Patch Peanut Allergy Treatment VITESSE Study
PRESS RELEASE published on 02/28/2026 at 20:25, 15 days 12 hours ago DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting DBV Technologies presents successful Phase 3 VITESSE study data at AAAAI Annual Meeting, highlighting VIASKIN Peanut Patch efficacy in treating peanut-allergic children DBV Technologies Food Allergies Viaskin Peanut Patch Phase 3 VITESSE Study AAAAI Annual Meeting
Published on 03/15/2026 at 23:25, 9 hours 59 minutes ago Tunkillia 'Phase 2' Resource Upgrade Drilling Begins
Published on 03/15/2026 at 18:00, 15 hours 24 minutes ago SEG Announced 2025 Annual Results Initiating First Special Dividend Distribution Payout Ratio Reached 88% Newly Signed Orders Exceeded RMB100-Billion Mark for the Second Consecutive Year
Published on 03/13/2026 at 23:00, 2 days 10 hours ago CORRECTION FROM SOURCE: EV Nickel Announces Maiden Mineral Resource Estimate for Gemini North Nickel Zone
Published on 03/13/2026 at 23:00, 2 days 10 hours ago Redwood AI Announces Platform Name Change and Appointment of Dr. Mark Dybul as Public Safety & Defense Advisor
Published on 03/13/2026 at 21:30, 2 days 11 hours ago Alset AI Announces Closing of Shares for Debt Transaction
Published on 03/16/2026 at 09:09, 15 minutes ago naoo Bridges Digital Engagement and Local Commerce with Launch of Generation V
Published on 03/16/2026 at 09:00, 24 minutes ago Homann Holzwerkstoffe reports solid operating performance of existing plants in the second half of 2025
Published on 03/13/2026 at 19:50, 2 days 13 hours ago Availability of ENGIE’S 2025 Universal Registration Document
Published on 03/13/2026 at 18:05, 2 days 15 hours ago Availability of the 2025 Universal Registration Document of OPmobility SE
Published on 03/13/2026 at 07:30, 3 days 1 hour ago BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
Published on 03/12/2026 at 18:00, 3 days 15 hours ago NEW OR RENEWED AGREEMENTS BETWEEN EURAZEO AND CERTAIN FAMILY SHAREHOLDERS
